Skip to main content
The Journal of Headache and Pain logoLink to The Journal of Headache and Pain
. 2022 Apr 28;23(1):51. doi: 10.1186/s10194-022-01422-y

Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)

Piero Barbanti 1,2,, Gabriella Egeo 1, Cinzia Aurilia 1, Florindo d’Onofrio 3, Maria Albanese 4,5, Ilaria Cetta 6, Paola Di Fiore 7, Maurizio Zucco 8, Massimo Filippi 9, Francesco Bono 10, Claudia Altamura 11, Stefania Proietti 12, Stefano Bonassi 12,13, Fabrizio Vernieri 14; and for the FRIEND-Study Group
PMCID: PMC9047372  PMID: 35484489

Correction to: J Headache Pain 22, 46 (2022)

https://doi.org/10.1186/s10194-022-01396-x

Following the publication of the original article [1], we were notified that the name of the 9th author was incorrectly spelled as Massimo FilippiBonassi, instead of Massimo Filippi.

The original article has been corrected.

Reference

  • 1.Barbanti P, et al. Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study) J Headache Pain. 2022;22:46. doi: 10.1186/s10194-022-01396-x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The Journal of Headache and Pain are provided here courtesy of BMC

RESOURCES